Company: HCWB
Filing Date: 2025-02-21
Form Type: DEF 14A
Source: 0001193125-25-032115
Chunk: 69

Company: HCW Biologics Inc.
Filing Date: 2025-02-21
Form: DEF 14A
Chunk 69
---
arkhill.com

If
to the Investor:

Square Gate Capital Master Fund, LLC – Series 4

40 Wall Street, Floor 28, Suite 2728

New York, NY 10005

E-mail: eloc@squaregatecapital.com

Attention: Christopher Perugini, Managing Partner

with a mandatory copy to (that shall not constitute notice) to:

Lucosky Brookman LLP

101 Wood
Avenue South

Woodbridge, NJ 08830

E-mail:

Attention: Seth Brookman

Either
party hereto may from time to time change its address or e-mail for notices under this by giving at least ten (10) days’ prior written notice of such changed
address to the other party hereto.

- A-21 -

Section 9.2 . The Company (an “”) agrees to indemnify and hold harmless the Investor along with its officers, directors, employees, and authorized agents and representatives, and each Person or entity, if any, who controls such party within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act or the rules and regulations thereunder (an “”) from and against any and all Damages, joint or several, and any and all actions in respect
thereof to which the Indemnified Party becomes subject to, resulting from, arising out of or relating to (i) any misrepresentation, breach of warranty or nonfulfillment of or failure to perform any covenant or agreement on the part of the
Indemnifying Party contained in this Agreement, (ii) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any registration statement pursuant to the Registration Rights Agreement or any
post-effective amendment thereof or supplement thereto, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, (iii) any untrue statement or
alleged untrue statement of a material fact contained in any preliminary prospectus or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or
alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading, or (iv) any material violation or alleged
material violation by the Company of the Securities Act, the Exchange Act, any state securities law or any